Research programme: diarrhoea therapies - Novartis/OneWorld Health
Latest Information Update: 23 May 2012
At a glance
- Originator Institute for OneWorld Health; Novartis
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Diarrhoea
Most Recent Events
- 23 May 2012 Early research is ongoing in USA
- 15 Jul 2009 Early research in Diarrhoea in USA (unspecified route)